Tag: peptide and oligonucleotide CDMO market outlook

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Peptide And Oligonucleotide CDMO Market from 2024 to 2033?
The peptide and oligonucleotide CDMO market has experienced rapid growth, anticipated to rise from $1.93 billion in 2023 to $2.16 billion in 2024, with a CAGR of 11.8%. This growth is attributed to rising demand for therapeutic agents, advancements in synthesis, and increased focus on antiviral peptides and mRNA vaccines.

The peptide and oligonucleotide CDMO market is expected to see rapid growth, projected to reach $3.39 billion in 2028 at a CAGR of 12.0%. Growth is driven by increasing demand for personalized medicine, advancements in biotechnology, expanding applications, rising outsourcing, and the growing burden of chronic diseases. Key trends include personalized therapies, technological advancements, quality control challenges, global expansion, and increased collaboration among biopharmaceutical companies.

Claim Your Free Sample of the Global Peptide And Oligonucleotide CDMO Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

What Key Factors Are Fueling the Growth of the Peptide And Oligonucleotide CDMO Market?
The increasing adoption of personalized medicine is expected to propel the peptide and oligonucleotide CDMO markets. Personalized medicine tailors healthcare decisions to individual characteristics such as genetics and lifestyle. This trend is fueled by advancements in genomic technologies and a demand for targeted treatments. Peptide and oligonucleotide CDMOs play a vital role in producing customized therapeutic products. For instance, in February 2024, the Personalized Medicine Coalition noted that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Thus, the growing adoption of personalized medicine is driving growth in the peptide and oligonucleotide CDMO market.

What Are the Major Segments of the Peptide And Oligonucleotide CDMO Market?
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

What New Trends Are Transforming the Peptide And Oligonucleotide CDMO Market?
Major players in the peptide and oligonucleotide CDMO market are forming strategic alliances to enhance service offerings, expand technological capabilities, and broaden their market reach. For example, in May 2023, PolyPeptide Group AG, a US-based CDMO, partnered with Germany’s Numaferm GmbH for peptide development. This collaboration leverages PolyPeptide’s cGMP manufacturing and market access, combined with Numaferm’s expertise in sustainable peptide production, to develop suitable peptide candidates for more sustainable peptide-based APIs.

Order Now for Fast Delivery of Your Peptide And Oligonucleotide CDMO Market Report!
https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regions Are Driving Growth in the Peptide And Oligonucleotide CDMO Market?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Peptide And Oligonucleotide CDMO Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the peptide and oligonucleotide cdmo market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Peptide And Oligonucleotide CDMO Market Include

1. Peptide And Oligonucleotide CDMO Market Executive Summary
2. Peptide And Oligonucleotide CDMO Market Segments
3. Peptide And Oligonucleotide CDMO Market Size And Template Market Growth Rate
4.  Key Peptide And Oligonucleotide CDMO Market Trends
5. Major Peptide And Oligonucleotide CDMO Market Drivers
……
25. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market
26. Top Peptide And Oligonucleotide CDMO Companies
27. Peptide And Oligonucleotide CDMO Market Opportunities And Strategies
28. Peptide And Oligonucleotide CDMO Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:
Biologics CDMO Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Peptide Antibiotics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Glycopeptide Antibiotics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Market Overview

The peptide and oligonucleotide contract development and manufacturing organization (CDMO) market has experienced significant growth in recent years.

• 2023 Market Size: $1.93 billion.
• 2024 Forecast: Expected to reach $2.16 billion, growing at a compound annual growth rate (CAGR) of 11.8%.
• 2028 Projection: Anticipated to reach $3.39 billion, with a CAGR of 12.0%.

Historical Growth Drivers

The growth in the historical period can be attributed to several factors:

• Therapeutic Demand: Increased demand for therapeutic agents.
• Technological Advancements: Progress in synthesis and manufacturing technologies.
• Personalized Medicine: Rising trends in personalized medicine.
• Regulatory Guidelines: Stricter regulatory frameworks boosting market confidence.
• Focus on Antivirals and mRNA: Enhanced focus on antiviral peptides and mRNA vaccines, showcasing the potential of oligonucleotides in vaccine development.

Read More On The Peptide And Oligonucleotide CDMO Market Report 2024 – https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Future Growth Drivers

The projected growth in the coming years is driven by:

• Personalized Medicine: Continued demand for tailored therapeutic solutions.
• Biotechnology Advancements: Innovations in biotechnology.
• Expanding Applications: Broader applications of peptides and oligonucleotides.
• Outsourcing: Increasing trend of outsourcing manufacturing and development.
• Chronic Diseases: Growing burden of chronic diseases requiring advanced therapies.

Major Trends

Several key trends are shaping the market:

• Personalized Therapies: Emphasis on custom treatments.
• Technological Advancements: Ongoing improvements in technology.
• Quality Control Challenges: Ensuring high-quality production standards.
• Global Expansion: Companies expanding their global footprint.
• Collaboration: Increased partnerships among biopharmaceutical companies.

Personalized Medicine: A Key Growth Driver

Personalized medicine is a significant growth driver in the peptide and oligonucleotide CDMO market.

• Tailored Treatments: Medical decisions and treatments based on individual characteristics such as genetics, environment, and lifestyle.
• Genomic Technologies: Advancements in genomic technologies facilitating personalized approaches.
• Disease Mechanisms: Better understanding of molecular-level disease mechanisms.
• FDA Approvals: For instance, the FDA approved 16 new personalized treatments for rare diseases in February 2024, up from 6 in 2022.

Strategic Partnerships Enhance Capabilities

Companies in the peptide and oligonucleotide CDMO market are forming strategic partnerships to boost their capabilities.

• Collaborative Agreements: Partnerships focused on developing and manufacturing peptide-based therapeutics.
• Example: In May 2023, PolyPeptide Group AG partnered with Numaferm GmbH to leverage their respective strengths in manufacturing and sustainable peptide production.

EUROAPI’s Acquisition of BianoGMP

EUROAPI made a strategic acquisition to strengthen its market position.

• Acquisition: In May 2024, EUROAPI acquired BianoGMP to enhance its capabilities in oligonucleotide CDMO services.
• Impact: This acquisition complements EUROAPI’s existing capacities, particularly in Frankfurt, and bolsters its market position.

Market Segmentation

The peptide and oligonucleotide CDMO market is segmented by product, service type, application, and end user.

• By Product: Peptides, Oligonucleotides.
• By Service Type: Contract Development, Contract Manufacturing.
• By Application: Therapeutics, Research Applications, Diagnostics, Other Applications.
• By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users.

Regional Insights

• North America: The largest region in the peptide and oligonucleotide CDMO market in 2023.
• Asia-Pacific: Expected to be the fastest-growing region during the forecast period, driven by advancements in biotechnology and increasing healthcare investments.

In summary, the peptide and oligonucleotide CDMO market is poised for robust growth, driven by personalized medicine, technological advancements, and strategic partnerships. As the demand for specialized therapeutic agents rises, the market will continue to expand, offering significant opportunities for companies in this sector.

Request for A Sample Of The Global Peptide And Oligonucleotide CDMO Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=15892&type=smp